These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 28213566

  • 1. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
    Burmester GR, McInnes IB, Kremer J, Miranda P, Korkosz M, Vencovsky J, Rubbert-Roth A, Mysler E, Sleeman MA, Godwood A, Sinibaldi D, Guo X, White WI, Wang B, Wu CY, Ryan PC, Close D, Weinblatt ME, EARTH EXPLORER 1 study investigators.
    Ann Rheum Dis; 2017 Jun; 76(6):1020-1030. PubMed ID: 28213566
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study.
    Takeuchi T, Tanaka Y, Close D, Godwood A, Wu CY, Saurigny D.
    Mod Rheumatol; 2015 Jan; 25(1):21-30. PubMed ID: 24720551
    [Abstract] [Full Text] [Related]

  • 3. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.
    Burmester GR, Feist E, Sleeman MA, Wang B, White B, Magrini F.
    Ann Rheum Dis; 2011 Sep; 70(9):1542-9. PubMed ID: 21613310
    [Abstract] [Full Text] [Related]

  • 4. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
    Weinblatt ME, McInnes IB, Kremer JM, Miranda P, Vencovsky J, Guo X, White WI, Ryan PC, Godwood A, Albulescu M, Close D, Burmester GR.
    Arthritis Rheumatol; 2018 Jan; 70(1):49-59. PubMed ID: 28941039
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis.
    Burmester GR, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, Szombati I, Esfandiari E, Sleeman MA, Kane CD, Cavet G, Wang B, Godwood A, Magrini F, EARTH Study Group.
    Ann Rheum Dis; 2013 Sep 01; 72(9):1445-52. PubMed ID: 23234647
    [Abstract] [Full Text] [Related]

  • 6. Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.
    Burmester GR, McInnes IB, Kremer JM, Miranda P, Vencovský J, Godwood A, Albulescu M, Michaels MA, Guo X, Close D, Weinblatt M.
    Arthritis Rheumatol; 2018 May 01; 70(5):679-689. PubMed ID: 29361199
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
    Taylor PC, Saurigny D, Vencovsky J, Takeuchi T, Nakamura T, Matsievskaia G, Hunt B, Wagner T, Souberbielle B, NEXUS Study Group.
    Arthritis Res Ther; 2019 Apr 18; 21(1):101. PubMed ID: 30999929
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z, Zhang F, Kay J, Fei K, Han C, Zhuang Y, Wu Z, Hsia EC.
    Int J Rheum Dis; 2016 Nov 18; 19(11):1143-1156. PubMed ID: 26259617
    [Abstract] [Full Text] [Related]

  • 9. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate.
    Genovese MC, Lee E, Satterwhite J, Veenhuizen M, Disch D, Berclaz PY, Myers S, Sides G, Benichou O.
    Ann Rheum Dis; 2013 Sep 01; 72(9):1453-60. PubMed ID: 23599435
    [Abstract] [Full Text] [Related]

  • 10. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy.
    Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B.
    Ann Rheum Dis; 2014 Sep 01; 73(9):1616-25. PubMed ID: 24699939
    [Abstract] [Full Text] [Related]

  • 11. Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.
    Guo X, Higgs BW, Bay-Jensen AC, Wu Y, Karsdal MA, Kuziora M, Godwood A, Close D, Ryan PC, Roskos LK, White WI.
    Rheumatology (Oxford); 2018 Jan 01; 57(1):175-184. PubMed ID: 29069507
    [Abstract] [Full Text] [Related]

  • 12. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
    Genovese MC, Fleischmann RM, Greenwald M, Satterwhite J, Veenhuizen M, Xie L, Berclaz PY, Myers S, Benichou O.
    Ann Rheum Dis; 2013 Sep 01; 72(9):1461-8. PubMed ID: 23268367
    [Abstract] [Full Text] [Related]

  • 13. Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial.
    Keystone EC, Genovese MC, Hall S, Bae SC, Han C, Gathany TA, Xu S, Zhou Y, Leu JH, Hsia EC.
    J Rheumatol; 2016 Feb 01; 43(2):298-306. PubMed ID: 26669912
    [Abstract] [Full Text] [Related]

  • 14. Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.
    Huizinga TW, Batalov A, Stoilov R, Lloyd E, Wagner T, Saurigny D, Souberbielle B, Esfandiari E.
    Arthritis Res Ther; 2017 Mar 09; 19(1):53. PubMed ID: 28274253
    [Abstract] [Full Text] [Related]

  • 15. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE, ATTRACT Study Group.
    Arthritis Rheum; 2005 Apr 09; 52(4):1020-30. PubMed ID: 15818697
    [Abstract] [Full Text] [Related]

  • 16. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO, Mendelsohn AM, Kim L, Xu Z, Leu J, Han C, Lo KH, Westhovens R, Weinblatt ME, GO-FURTHER Investigators.
    Arthritis Care Res (Hoboken); 2015 Dec 09; 67(12):1627-36. PubMed ID: 25623393
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D, Bingham CO, Tanaka Y, Agarwal P, Kurrasch R, Tak PP, Popik S.
    Lancet; 2017 Mar 25; 389(10075):1206-1217. PubMed ID: 28215362
    [Abstract] [Full Text] [Related]

  • 18. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK.
    J Rheumatol; 2003 Dec 25; 30(12):2563-71. PubMed ID: 14719195
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
    Kavanaugh A, Kremer J, Ponce L, Cseuz R, Reshetko OV, Stanislavchuk M, Greenwald M, Van der Aa A, Vanhoutte F, Tasset C, Harrison P.
    Ann Rheum Dis; 2017 Jun 25; 76(6):1009-1019. PubMed ID: 27993828
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.